The Top 5: June 2018

2nd July 2018 (Last Updated December 10th, 2018 16:07)

CTA highlights the best articles from the month of June 2018

The Top 5: June 2018

There were numerous articles in June 2018 that covered a wide range of topical issues. Here are five of the best stories you might have missed... (Click the headline to finish reading the story)

The Strive to Incorporate Machine Learning into Clinical Development

The utilization of machine learning in the design, conduct and interpretation of clinical trials has been eagerly anticipated. Machine learning has the potential to increase the efficiency of almost every aspect of medical research from identifying appropriate patients to optimizing strategies to send study supplies to clinical sites. The advent of electronic tools to medical research parallels the expectation of precision medicine for patients, improving benefit while reducing risk.

We Need to Talk About Race: Lack of Diversity in Clinical Trials is a Public Health Issue

The persistent lack of diversity among clinical trial participants, and the resulting lack of data on multi-ethnic patient bases, requires us to consider the implications of this situation before we can address possible solutions.

It may seem obvious, but it is worth stating: when segments of the population are not included in clinical trials at levels that do not meet statistical significance, it is impossible to determine if the therapy in question will work equally, better, or worse as for the population in which it is studied.

Innovation in Clinical Supply Management

Clinical supply management is facing a number of challenges in a rapidly changing environment which necessitates constant adjustments. Innovations enable the clinical supply chain to brace for upcoming challenges.

In pharmaceutical and clinical development, the customer and the sponsor have different views on innovation and improvement. However, there are also aspects which are of utmost importance for both parties, such as patient safety, study adherence, compliance, and others.

Increasing Transparency and Building Relationships between Sponsors and CROs

“All CROs are the same,” my CMO said to me shortly after I joined a new pharma company. “They all say great things but you can’t count on them to deliver. I wish we still had our own study teams filled with CRAs and assistants and…” – his voice trailed off wistfully as he remembered the glory days of clinical operations departments well-stocked with fully trained staff delivering concierge site management services. I remember those days too and I sympathize, but as we all know, clinical trial management has left that era some time ago, and in its place most pharma and biotech companies have trimmed down our in-house resources to become increasingly dependent upon the services of external resource providers, such as full-service CROs, with varying degrees of success.

Salary Survey: Study Indicates Industry Values Experience Over Education

In 2017, Clinical Trials Arena conducted its first ever salary survey, with the aim of gauging the current state of the life sciences jobs market. Over 200 industry professionals took part in the study, all of whom were attendees of Arena International’s global series of clinical events. Insight from respondents across the world allowed CTA to glean where professions in the life sciences are heading, as well as what individuals look for in both their current roles and when they seek new challenges.

We would like to take this opportunity to extend our deepest thanks to all those who participated in our survey. It is one of the only salary surveys specific to the life sciences industry that looks to provide invaluable data for both hiring managers and industry professionals. The survey opens the door to greater salary transparency, providing a snapshot of what you can expect to earn relative to your skills, experience and location. The results illustrate and confirm the ongoing growth and success of careers within the life sciences industry.

 

In case you missed Supply Chain Week last month, click here to read exclusive articles delving into the current issues and concerns involving oncology trials.

PHOTO CREDIT: Rob Nguyen